Join US - 30 May, 10:30am (CET)

Join us for our webinar in occasion of World Multiple Sclerosis Day, presented with the participation of MS International Federation (MSIF).

We will explore the journey to the inclusion of rituximab, glatiramer acetate, and cladribine on the WHO Essential Medicines List, now reshaping access to MS treatments worldwide. We will focus on the fundamental role of robust evidence in achieving this milestone and share insights into the application process.

Don't miss this opportunity and watch the recording here: Global Recognition of MS Drugs: from Evidence-Synthesis to Action 

Our speakers for this webinar were:

• Nick Rijke, Access to Healthcare Consultant for MSIF - Building an application for WHO EML: the case of MSIF
• Francesco Nonino, Joint Coordinating Editor of Cochrane MS and Rare Diseases of the CNS & Director of WHO Collaborating Centre in Evidence-Based Research Synthesis and Guideline Development - Evidence Synthesis on MS treatments to inform decision making at a global level